Call for Abstract

18th International Conference on Vaccine Adjuvants and Delivery Technologies, will be organized around the theme “Discussion on latest research and technologies in Vaccine adjuvants & delivery systems”

Vaccines Delivery 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vaccines Delivery 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Vaccine adjuvants are needed to improve the adaptive immune responses to antigens. Adjuvants show their effects through different mechanisms. Some adjuvants work as delivery systems that provide stimulation of the immune system. Immunologic adjuvants are added to vaccines for the stimulation of the response of immune system to the target antigen, but directly do not provide immunity. Adjuvants may act in various ways to present an antigen in the immune system. Adjuvants may also act as the irritant to engage and amplify the body immune response.

 

  • Track 1-1Vehicle Adjuvants
  • Track 1-2Mineral Salt Adjuvants
  • Track 1-3Bacteria Derived Adjuvants
  • Track 1-4Adjuvant Emulsions
  • Track 1-5Liposome Adjuvants
  • Track 1-6Polymeric Microsphere Adjuvants
  • Track 1-7Cytokines as Adjuvants
  • Track 1-8Carbohydrate Adjuvants

The development of the new delivery system has increased the hope of patient safety and efficacy of vaccines. A remarkable development in vaccine delivery technologies are observed now-a-days. The reason for developing vaccines as controlled drug delivery system is the failure of Immunization system with conventional immunization regimen that involves prime doses and booster doses. Generally patients neglect the latter doses. On the other hand vaccines delivery systems allow the incorporation of doses of antigens so that the release of antigens occurs slowly in a controlled manner and booster doses are no longer needed. It controls the temporal and spatial presentation of antigens to the immune system to promote their targets straight to the immune cells.

 

  • Track 2-1Delivery Systems and Formats
  • Track 2-2Systems Vaccinology
  • Track 2-3Monovalent Vaccines
  • Track 2-4Oral Vaccines
  • Track 2-5Intra-nasal Vaccine
  • Track 2-6Transdermal Delivery of Vaccines
  • Track 2-7Routes of Vaccine Delivery System
  • Track 2-8Medical Devices for Vaccine Delivery

The patient safety and efficacy of adjuvants are highly required as the vaccines are one of the lifesaving agents. Therefore, the FDA and CDC rules regarding the vaccine adjuvants are highly essential during vaccine formulation and manufacturing processes. CBER of FDA is responsible for vaccine regulation in the United States. Vaccine development process follows the same pathway as for drugs and other pharmaceutical agents. A sponsor must submit the Investigational New Drug application (IND) to FDA. The IND describes about the vaccine, quality control tests for release, and its method of manufacture. After the successful completion of all three phases of clinical development the Biologics License Application (BLA) are submitted. After getting the permission form FDA and CDC a vaccine may be marketed.

 

  • Track 3-1FDA Approved Vaccine Adjuvants
  • Track 3-2Factors Effecting Vaccine Preservation
  • Track 3-3Efficacy of Vaccines in Newborns
  • Track 3-4Pre-Formulation & Formulation Aspects
  • Track 3-5Vaccine Ingredients
  • Track 3-6Sudden Infant Death Syndrome (SIDS)
  • Track 3-7Vaccines During Pregnancy
  • Track 3-8Vaccine Injury Compensation Programme

The vaccine adjuvants market is dependent on different factors like, product type, disease type, application type, etc. The major causes that drive the growth of this market are widespread of infectious and zoonotic diseases, increasing concern on immunization programs, and growing demands of improved and long-lasting immunization against diseases. Based on the product type, the vaccine adjuvants market is classified into adjuvant emulsions, pathogen components, combination adjuvants, particulate adjuvants, and others. On the basis of the type of disease, the vaccine adjuvants market is classified into infectious diseases, cancer, and others. The infectious diseases segment is expected to have the largest share of the global market in 2016. Based on applications, the market is classified into research and commercial applications. Growth in these segments are influenced by factors such as increasing initiatives by government bodies and companies, ongoing research projects on new adjuvants, increasing incidences of zoonotic diseases, and growing usage of many vaccine adjuvants commercially. Based on the application categories, the market is classified into human vaccine adjuvants and veterinary vaccines adjuvants.

 

  • Track 4-1Hepatitis Vaccines
  • Track 4-2Influenza Vaccines
  • Track 4-3HIV Vaccines and Therapeutics
  • Track 4-4Adjuvants for DNA Immunisation
  • Track 4-5Cancer Vaccine Adjuvants
  • Track 4-6Vaccines Business
  • Track 4-7Immunogenic Proteins
  • Track 4-8Shelf-life of Adjuvants

Biomarkers or biological markers are a measurable indicator of some biological condition. The term is also used to refer to a substance that indicates the presence of a living organism. Biomarkers show the extent to which the vaccine is active and they characterize the nature of response of the vaccine. The biomarkers are important to measure the potency and safety of vaccine adjuvants.

  • Track 5-1Adjuvant Safety Issues
  • Track 5-2Adjuvant Regulatory Requirements
  • Track 5-3Alum Based Adjuvants
  • Track 5-4Novel Marker Vaccine
  • Track 5-5Vaccines and Adjuvants Mechanisms of Action
  • Track 5-6Vaccine Quality Control
  • Track 5-7Advancement in Vaccine-Induced-Immunity
  • Track 5-8Biomarkers of Mucosal and Skin Immunity

The development of vaccine has achieved an evolutionary path. With the help of pharmaceutical nanotechnology we can formulate the efficient vaccine delivery systems that can maintain a sustained release to induce the immune-stimulatory properties of the vaccine. Formulations based on nanotechnology offer multiple advantages in vaccine developments. Nanocarriers such as polymeric particles, liposomes, lipid nanoparticles, virosomes etc. help in improving the immunogenicity in the new generation of vaccines. This nanocarrier systems help to improve vaccine stability, protect the vaccines from degradation, help in targeting of the antigen to the antigen presenting cells (APCs) and provide adjuvant effect.

 

  • Track 6-1Polymeric Nanoparticles
  • Track 6-2Micro-Particles
  • Track 6-3Antigen Presenting Cells
  • Track 6-4Dendrimers
  • Track 6-5Advantages of Nanotechnology
  • Track 6-6Liposomes
  • Track 6-7Virosomes
  • Track 6-8Intra-Dermal Injections

Vaccines that protect people against viral diseases like HIV/AIDS, cervical cancer and other infectious diseases like hepatitis are the novel vaccines. This is a delicate balancing act: If the response of the immune system to the vaccine is too strong, toxic effects may kill the patient but if it is not strong enough, the virus may spread faster than the immune system can kill it. The quality of vaccine can be improved by incorporating immunomodulators or adjuvants with modified delivery vehicles. Adjuvant may also be included in vaccine to regulate the type of immune response generated. This can be important when developing vaccine for human immunodeficiency virus (HIV), cancer, or mucosal immune system.

  • Track 7-1Adult Immunization Challenges
  • Track 7-2Diabetes Vaccines
  • Track 7-3Immune-Informatics in Vaccine Designs
  • Track 7-4Vaccines for Chronic Infections
  • Track 7-5Age Specific Immune Responses
  • Track 7-6Traveller Vaccinations
  • Track 7-7Infections in HIV Patients
  • Track 7-8Malaria Vaccines

The major aims of veterinary vaccines are to improve the health and welfare of animals, increase production of farm animals in an economic manner, and prevent transmissions of infectious diseases from both domestic animals and wildlife to the humans. The developments of veterinary vaccines are proceeding through genetically engineered organisms, vectored antigen formulations, and naked DNA injections. These veterinary vaccines have a major impact not only on animal health but also on human health through preventing animal-to-human transmission of infectious diseases. The constant interaction between human and animals researchers will be of major importance for finding new technologies. There are so many severe diseases that are spread from the domestic and wild animals to the human, so it is important to be concerned about the immunization processes of animals.

  • Track 8-1Veterinary Viral Vaccines
  • Track 8-2Vaccines Against Zoonotic Bacteria
  • Track 8-3Small Pox Vaccine
  • Track 8-4DIVA Vaccines
  • Track 8-5IBR Vaccines
  • Track 8-6Fertility Regulating Vaccines
  • Track 8-7ELISA Techniques
  • Track 8-8Rabies Vaccine

The discovery of vaccines has provided safety against several important diseases and has had a great impact on health for a relatively low cost. The introduction of genetic engineering has influenced rapid advances in vaccine technology. Functional genomics has become a powerful tool for all vaccine researchers. The necessity of effective and safer vaccines influences a large number of experiments in all vaccine development stages. The increasing number and type of vaccine will undoubtedly create new challenges to the market.

  • Track 9-1Recent Advances in Delivery Systems
  • Track 9-2Development of Delivery System
  • Track 9-3Dendritic Vaccine Delivery System
  • Track 9-4Mucosa Immunization Industries
  • Track 9-5Vaccine Innovation
  • Track 9-6Vaccine Interaction
  • Track 9-7Ready to Use Inactivated Vaccine
  • Track 9-8Synthetic Antigens

The new era in vaccine designing has changed the old concepts about the discomforts and difficulties of vaccine acceptance to common people. It has increased the safety and efficacy of the vaccines and has made the delivery processes easier. Vaccines are of mainly two types, prophylactic, or therapeutic. The agent of vaccine influences the body's immune system to identify the foreign agent, destroy it, and "remember" it so that the immune system can more easily identify and destroy any of the pathogenic microorganisms in future.

 

  • Track 10-1Molecular Signatures Immunogenicity
  • Track 10-2Live Vector Vaccines
  • Track 10-3Particle-based Vaccines
  • Track 10-4Conjugate Vaccines
  • Track 10-5Child Vaccination & Immunization
  • Track 10-6Mucosal Immunity to Stealth Pathogens
  • Track 10-7Vaccine Needle
  • Track 10-8Liquid Vaccines
  • Track 10-9Targeting Delivery System

Developing a vaccine against several diseases remains a challenge. Vaccine Research & Development is very complex and costly because a vaccine is a biological product that is made from the living microorganisms. Therefore, its development cycle is quite different from the other pharmaceutical products. There are so many microbes that can cause disease, and the goal for a vaccine is to protect against all of them. There is limited understanding of how severe disease occurs and how the microbes interacts with the immune system. Several vaccine candidates are in clinical stages of development. The pre-clinical development stage is the first step to identify a vaccine candidate that determines a vaccine’s ultimate safety profile. Phase I trials is the stage where the researchers test the candidate vaccine for the first time in humans to evaluate its safety, safe dosage range, and vaccine-related side effects. Phase II trials is the stage where the candidate vaccine is administered to a larger group of people for the evaluation of its immunogenicity and safety. The goal of phase III is to conduct a large-scale safety and efficacy study on a relevant patient population. It is really very complex to market a new vaccine and once it has been marketed, pharmacovigilance activities take place in order to conduct a strict safety supervision of that vaccine.

  • Track 11-1Product Development for Vaccines
  • Track 11-2HIV Vaccine Research
  • Track 11-3Polymeric Nanoparticle Delivery
  • Track 11-4Approaches to Mucosal-Vaccines
  • Track 11-5Global Vaccine
  • Track 11-6Surveillance, Assessment and Monitoring
  • Track 11-7Meningitis Vaccine Project (MVP)
  • Track 11-8Pre-Clinical and Clinical Development

The study of inheritance of human beings is known as Human Genetics. Human genetics includes a variety of fields, such as: classical genetics, cytogenetics, molecular genetics, biochemical genetics, genomics, population genetics, developmental genetics, clinical genetics, and genetic counselling. Study of human genetics may be useful to understand the diseases and find the effective disease treatment, the effect way to vaccine development and understand the genetics of human life.

  • Track 12-1Recombinant Vaccines
  • Track 12-2DNA and RNA Based Vaccines
  • Track 12-3Vaccines and Genetic Mutation
  • Track 12-4Genetic Exchanges
  • Track 12-5Vaccine Antigens
  • Track 12-6Genetic Hybridization
  • Track 12-7Stealth Viruses
  • Track 12-8Humoral Immunity

A vaccine is a biological agent that provides active acquired immunity to a particular disease. A vaccine typically contains a component that seems like a disease-causing microbe and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. Vector is an organism that transfers a pathogen from reservoir to host. Traditional approach of live-attenuated vaccine immunization has resulted in remarkable success in the reduction and control of infectious disease. But many pathogens remain less responsive to the traditional vaccine strategies. Therefore, more appropriate vaccine strategies are needed. Recent discovery on the field of viral molecular biology and genetics has provided the opportunity to use viruses as vaccine platforms and as potential anti-cancer agents. Now-a-days viral vectors are considered as an attractive to the traditional platforms.

An adjuvant is an ingredient of that helps create a stronger immune response in the human body.  In short, adjuvants help vaccines work more efficiently. Drug delivery refers to approaches, formulations, and techniques for administering a pharmaceutical compound in the body to safely achieve its desired therapeutic effect. Both the vectors, adjuvants and delivery system are important to get the safe action of a vaccine.

 

  • Track 13-1Mucosal Vaccines, Adjuvants
  • Track 13-2DAMP/PAMP Mechanism
  • Track 13-3Quality and Safety of Vaccines
  • Track 13-4Emulsion Delivery System
  • Track 13-5Solid Particulate Vaccine Delivery
  • Track 13-6Needle Free Delivery System
  • Track 13-7Micro Needle
  • Track 13-8Vaccine Acceptability

The therapeutic vaccines that fight against the chronic infectious diseases aim to obtain a strong immune response. The development of these vaccines will help to find a new way to gain protection against severe diseases. The New Vaccine techniques have opened up new opportunities to vaccine development. There are a number of scientific challenges to solve the problems in the development of new vaccines.

  • Track 14-1Cancer Vaccines
  • Track 14-2AIDS/HIV Vaccines
  • Track 14-3Measles, Mumps, Rubella Vaccines
  • Track 14-4Salmonella Vaccine Strain
  • Track 14-5Japanese Encephalitis Vaccine
  • Track 14-6Pneumococcal Polysaccharide Vaccine
  • Track 14-7Gene Vaccine
  • Track 14-8Toxoid Vaccine
  • Track 14-9Whole-organism Vaccines

Immunology is the study of immune systems in all organisms. The induction of protective immunity in a sufficient proportion is required for disease control or elimination. This can be best achieved by immunization programs that are capable of inducing long-term protection. The key to use pre-clinical studies in animal models is to select the one having similarities to human tissues so that it can easily show the condition of a disease state similar to human. Through animal model we can study the immunology and the physiological effect of vaccines.

 

  • Track 15-1HPV Vaccine
  • Track 15-2Influenza (Swine Flu) Vaccine
  • Track 15-3Skin Cancer
  • Track 15-4Foot and Skin Diseases
  • Track 15-5TB Vaccine Trial
  • Track 15-6Meningitis B
  • Track 15-7Host-Pathogen Interactions
  • Track 15-8Bioinformatics